After decades of slow progress in understanding and developing effective treatments for Alzheimer’s disease, scientists are ...

Alzheimer's disease affects millions of people worldwide, yet the illness is hardest to catch at the very beginning, when new ...

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

The findings could help clinicians use neuropsychiatric symptoms to prepare patients and families for a type of dementia ...

In the brain, Alzheimer’s is characterized by two proteins, amyloid beta and tau, that become dysfunctional, forming plaques ...

Researchers say they have developed a blood test that can help predict the start of Alzheimer's disease symptoms, allowing them to receive a diagnosis.

Research from UC Santa Cruz indicates that the P3 peptide—an alternative cleavage product of the amyloid precursor protein—may play a role in Alzheimer’s disease.

New findings suggest that targeting inflammation in Alzheimer’s may matter as much as targeting protein buildup.

Some people with the gene did not have expected outcomes if they were heavy meat-eaters ...

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...

Have you ever wondered how an Alzheimer’s patient literally views the world and what they experience in the confusion? Now, families and caregivers can have the experience through special goggles ...

Now, with the passing of House Bill 565, also known as Jill’s Law, all Mississippians will have access to biomarker testing ...